Shanghai Shyndec Pharmaceutical's subsidiary obtains the drug registration certificate for Tafurinol eye drops.
Guoyao Xianzhong (600420.SH) announced that its holding subsidiary, Guoyao Group Sanyi Pharmaceuticals (Wuhu) Co., Ltd., recently received the drug registration certificate for Tafurinol eye drops issued by the National Medical Products Administration. Tafurinol eye drops are a medication used to lower eye pressure, suitable for patients with elevated eye pressure due to open-angle glaucoma and high intraocular pressure.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that its controlling subsidiary, Guoyao Group Sanyi Pharmaceutical (Wuhu) Co., Ltd., recently received the National Medical Products Administration's approved and issued drug registration certificate for Tafluprost Eye Drops. Tafluprost Eye Drops is a medication used to lower eye pressure and is suitable for patients with increased eye pressure from open-angle glaucoma and ocular hypertension.
Related Articles
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
WuXi AppTec (02359) spent 102 million Hong Kong dollars on repurchasing 818,000 shares on June 15th.
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
WuXi AppTec (02359) spent 102 million Hong Kong dollars on repurchasing 818,000 shares on June 15th.
RECOMMEND
